Cost-benefit analysis

Material provided: Report
Unit definition: 3 person months
Provider country: Netherlands (AIGHD, NIVEL)
Short description: Evaluation of costs and benefits associated with epidemic interventions, resulting in a report to be delivered at end of service.

Description

1) What we offer as in the general steps of a cost-benefit analysis, what it takes to get there;

This service includes guidance and supervision on the design and conduction of cost-benefit analysis to assess ‘value for money’ of the interventions that are piloted and implemented by researchers across Europe to make societies more prepared for a new pandemic. Health economists can support them in incorporating economic evaluations into their research projects. Moreover, together they can ensure that this type of analysis captures and values interventions’ impact from a comprehensive perspective using economic metrics that ultimately benefit health and welfare of populations, especially vulnerable ones.

This service will develop a framework for the conduct of cost-benefit analyses of pandemic preparedness interventions. The impact of ill health on a person’s life course will be captured by metrics such as QALYs, DALYs (quality-adjusted life-years and disability-adjusted life-years) that combine the years lived while suffering from a health condition and years of life lost due to premature death. Economic metrics such as healthcare utilization, informal care, and productivity losses due to diseases will be used to assess the financial consequences related to the evaluated interventions and diseases. These metrics will be collected in clinical studies assessing the developed interventions but will also provide inputs to population-wide models estimating the cost and benefits associated with health interventions under different epidemic scenarios. In this way, the results will support decision-makers to decide how to timely allocate limited resources in such a way that benefits society the most.

Steps

    – To design a framework for the conduct of cost-benefit analyses alongside clinical studies aiming to evaluate interventions from a societal perspective that can be adapted to other infectious diseases and different population contexts.
    – To develop a generic model that can be used for cost-benefit analyses of interventions under different epidemic scenarios.
    – To develop web-based applications to support the use of developed cost-benefit analysis by healthcare decision makers.

 

2) how much time reasonably can be expected this may take, e.g. range from a week (fulltime) or several weeks to months?

     – Developing the framework: 6 months
     – Developing the generic model: 12 months
    – Conduct specific case cost-benefit analyses: 1-3 months

 

3) What kind of cost-benefit economics expertise can support this? 

The team of health economists has expertise on conducting applied cost-benefit analysis, also referred to as cost-effectiveness studies, and the development of new methods for economic evaluations performed alongside clinical trials, observational studies, and more recently using real world data, but also using modelling techniques.

 

The ISIDORe project has received funding from the EU Horizon Europe research and innovation programme under grant agreement No. 101046133.

A note on language
Select language